These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24608124)

  • 1. Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis.
    Link J; Lundkvist Ryner M; Fink K; Hermanrud C; Lima I; Brynedal B; Kockum I; Hillert J; Fogdell-Hahn A
    PLoS One; 2014; 9(3):e90479. PubMed ID: 24608124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.
    Núñez C; Cénit MC; Alvarez-Lafuente R; Río J; Fernández-Arquero M; Arroyo R; Montalbán X; Fernández O; Oliver-Martos B; Leyva L; Comabella M; Urcelay E
    J Med Genet; 2014 Jun; 51(6):395-400. PubMed ID: 24748646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
    Hegen H; Schleiser M; Gneiss C; Di Pauli F; Ehling R; Kuenz B; Lutterotti A; Berger T; Deisenhammer F
    Mult Scler; 2012 May; 18(5):610-5. PubMed ID: 22013146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.
    Pachner AR; Warth JD; Pace A; Goelz S;
    Neurology; 2009 Nov; 73(18):1493-500. PubMed ID: 19884577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P; Calabrese M; Biasi G; Gallo P
    J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
    Buck D; Andlauer TF; Igl W; Wicklein EM; Mühlau M; Weber F; Köchert K; Pohl C; Arnason B; Comi G; Cook S; Filippi M; Hartung HP; Jeffery D; Kappos L; Barkhof F; Edan G; Freedman MS; Montalbán X; Müller-Myhsok B; Hemmer B;
    Mult Scler; 2019 Apr; 25(4):565-573. PubMed ID: 29521573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
    Bertolotto A; Malucchi S; Milano E; Castello A; Capobianco M; Mutani R
    Immunopharmacology; 2000 Jul; 48(2):95-100. PubMed ID: 10936507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
    Jungedal R; Lundkvist M; Engdahl E; Ramanujam R; Westerlind H; Sominanda A; Hillert J; Fogdell-Hahn A
    Mult Scler; 2012 Dec; 18(12):1775-81. PubMed ID: 22551640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
    Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
    J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes.
    Deisenhammer F
    CNS Drugs; 2009; 23(5):379-96. PubMed ID: 19453200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
    Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Goodin DS; Frohman EM; Hurwitz B; O'Connor PW; Oger JJ; Reder AT; Stevens JC
    Neurology; 2007 Mar; 68(13):977-84. PubMed ID: 17389300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive.
    Khan OA; Dhib-Jalbut SS
    Neurology; 1998 Dec; 51(6):1698-702. PubMed ID: 9855525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.
    Goodin DS; Hartung HP; O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Jeffery D; Kappos L; Bogumil T; Knappertz V; Sandbrink R; Beckmann K; White R; Petkau J; Pohl C;
    Mult Scler; 2012 Feb; 18(2):181-95. PubMed ID: 21952094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
    Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients.
    Sato DK; Nakashima I; Fukazawa T; Shimizu Y; Tomizawa Y; Yokoyama K; Misu T; Creeke PI; Farrell R; Giovannoni G; Itoyama Y; Fujihara K; Aoki M
    Tohoku J Exp Med; 2012 Oct; 228(2):85-92. PubMed ID: 22976494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta.
    Lundkvist M; Greiner E; Hillert J; Fogdell-Hahn A
    Mult Scler; 2010 Jul; 16(7):796-800. PubMed ID: 20534645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.